Institute for Glycomics
Griffith University
The Institute's multidisciplinary approach to drug and vaccine discovery research spans infectious disease, cancer and structural biology, medicinal and computational chemistry. Research is based, in part, on the study of carbohydrates or sugars, which are involved in many biological processes and particularly in disease. The Institute is one of the largest in the world dedicated to this complex and emerging field. With access to world-class facilities, the Institute's research programs offer an exciting platform for the diagnosis and control of a wide range of medical conditions such as blood and metastatic cancers, diabetes, parasite, viral, fungal and bacterial infectious diseases, inflammation and immune disorders. Researchers at the Institute seek to collaborate with leading scientists around the world to build a critical mass around this multidisciplinary research.
- Website
- https://www.griffith.edu.au/institute-glycomics
- Organisation type
- University Research Centre
- Number of research staff
- 20-100 research staff
- Address
- Building G26, Griffith University (Gold Coast campus), Parklands Drive, Southport QLD 4215
Strengths and capabilities
- Drug, vaccine and diagnostic discovery for infectious diseases and cancer
- Discovery science through to phase 1 human clinical trials
- Comprehensive multidisciplinary approach
- All facets of glycomics research
- Medicinal and computational chemistry
- Structural biology
- Microbiology
- Technology out-licencing to biotechnology and pharmaceutical companies
- Glycomics platform technologies
- Comprehensive glycomics bioanalytical facilities and services
Facilities and major equipment
- Medicinal chemistry laboratories
- Computational chemistry and visualisation facility
- Biochemistry and molecular biology facility
- Microbiology laboratories
- Physical containment 2 (PC2) and 3 (PC3) facilities
- Bioanalytical facility
- Protein x-ray crystallography facility
- Flow cytometery and cell-sorting facility
- Nuclear magnetic resonance spectroscopy facility
- Joint laboratory for quantum molecular biophysics
Lead researcher
- Professor Mark von Itzstein—Co-inventor of Relenza - marketed by GSK for influenza
- Professor Michael Good AO—Leading research and clinical trials for malaria and Group A Strep vaccines
- Professor Michael Jennings—World-leading expertise in microbiology
Key science sectors
More information about the sectors this centre is involved in:
Update details
Is this your centre? See any issues? Send a request to update your listing.